- Home
- RPRX vs PCVX Comparison
RPRX vs PCVX Comparison
Compare RPRX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- PCVX
- Stock Information
- Founded
- RPRX 1996
- PCVX 2013
- Country
- RPRX United States
- PCVX United States
- Employees
- RPRX 89
- PCVX N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- RPRX Health Care
- PCVX Health Care
- Exchange
- RPRX Nasdaq
- PCVX Nasdaq
- Market Cap
- RPRX 13.6B
- PCVX 10.6B
- IPO Year
- RPRX 2020
- PCVX 2020
- Fundamental
- Price
- RPRX $30.93
- PCVX $90.93
- Analyst Decision
- RPRX Strong Buy
- PCVX Strong Buy
- Analyst Count
- RPRX 6
- PCVX 9
- Target Price
- RPRX $41.67
- PCVX $149.38
- AVG Volume (30 Days)
- RPRX 3.4M
- PCVX 1.3M
- Earning Date
- RPRX 02-13-2025
- PCVX 02-25-2025
- Dividend Yield
- RPRX 2.74%
- PCVX N/A
- EPS Growth
- RPRX 518.56
- PCVX N/A
- EPS
- RPRX 2.55
- PCVX N/A
- Revenue
- RPRX $2,266,003,000.00
- PCVX N/A
- Revenue This Year
- RPRX $14.54
- PCVX N/A
- Revenue Next Year
- RPRX $10.94
- PCVX N/A
- P/E Ratio
- RPRX $11.99
- PCVX N/A
- Revenue Growth
- RPRX N/A
- PCVX N/A
- 52 Week Low
- RPRX $24.05
- PCVX $58.10
- 52 Week High
- RPRX $31.66
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- RPRX 75.82
- PCVX 55.05
- Support Level
- RPRX $29.73
- PCVX $83.96
- Resistance Level
- RPRX $31.09
- PCVX $90.73
- Average True Range (ATR)
- RPRX 0.73
- PCVX 4.01
- MACD
- RPRX 0.28
- PCVX 1.13
- Stochastic Oscillator
- RPRX 93.94
- PCVX 93.41
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.